NEW YORK–(BUSINESS WIRE)– Replicor Inc., een niet-beursgenoteerd biofarmaceutisch bedrijf dat streeft naar een medicijn tegen chronische hepatitis B en tegen een co-infectie van chronische hepatitis B en hepatitis delta, presenteert preklinische en geüpdatete klinische gegevens over combinatietherapieën op basis van REP 2139-Ca tegen hepatitis B en de co-infectie van hepatitis B en hepatitis delta. Dat doet het bedrijf op de 25e jaarvergadering van de Asia Pacific Association for the Study of the Liver, dat van 20 tot 24 februari 2016 plaatsvindt in Tokyo. Replicor geeft drie presentaties over zijn technologie.
Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016
NEW YORK–(BUSINESS WIRE)– Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and updated clinical data on REP 2139-Ca based combination therapies in HBV infection and HBV / HDV co-infection at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver to be held from February 20 -24, 2016 in Toyko, Japan. Three presentations on Replicor technology will be made during the meeting:
HBV RNA is emerging as a potential new marker of viremia in patients with HBV infection. In patients with HBeAg positive HBV infection, treatment with REP 2139-Ca and immunotherapy (in the REP 102 protcol), not only leads to reduction / clearance of HBsAg and HBV DNA and the appearance of anti-HBs but also to reduction of HBV RNA as well. The characterization of the HBV RNA response in the REP 102 protocol was done in collaboration with the lab of Dr. Hendrik Reesink at the Amsterdam Medical Center, and will be presented by Dr. Reesink in the Presidential Plenary Session on February 22 nd.
An update on the clinical response data from HBV /HDV co-infected patients completing REP 2139-Ca / peg-interferon combination therapy and transitioning to peg-interferon monotherapy in the REP 301 protocol will be presented in an oral presentation on Feb 22 nd (O-130).
A poster presentation on the effects of combined treatment with REP 2139-Ca and tenofovir disoproxil fumarate and entecavir on serum and liver virema in vivo will be presented on Feb 22 nd (P-0329).
These pre-clinical and clinical studies continue to advance Replicor’s understanding of the antiviral effects of REP 2139-Ca based combination therapies and how these can be used to benefit patients with HBV infection or HBV / HDV co-infection.
For the APASL 2016 meeting and preliminary program:
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website atwww.replicor.com.
For Replicor Inc.
Alexandra Peterson, 212-508-9709